An overview of COVID-19

Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11, 2020, the World Health Organization (WHO) officially named the disease resulting from infection with SARS-CoV-2 as coronavirus disease 2019 (COVID-19). COVID-19 represents a spectrum of clinical manifestations that typically include fever, dry cough, and fatigue, often with pulmonary involvement. SARS-CoV-2 is highly contagious and most individuals within the population at large are susceptible to infection. Wild animal hosts and infected patients are currently the main sources of disease which is transmitted via respiratory droplets and direct contact. Since the outbreak, the Chinese government and scientific community have acted rapidly to identify the causative agent and promptly shared the viral gene sequence, and have carried out measures to contain the epidemic. Meanwhile, recent research has revealed critical aspects of SARS-CoV-2 biology and disease pathogenesis; other studies have focused on epidemiology, clinical features, diagnosis, management, as well as drug and vaccine development. This review aims to summarize the latest research findings and to provide expert consensus. We will also share ongoing efforts and experience in China, which may provide insight on how to contain the epidemic and improve our understanding of this emerging infectious disease, together with updated guidance for prevention, control, and critical management of this pandemic. 2019 年 12 月中国湖北省武汉市爆发由严重急性呼吸综合征冠状病毒 2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) 感染引起的新型冠状病毒肺炎. 2020 年 2 月 11 日, 世界卫生组织 (World Health Organization,WHO) 将该疾病正式命名为COVID-19(coronavirus disease 2019). COVID-19 临床表现多样, 典型表现为发热、 干咳和乏力, 常出现肺部受累. SARS-CoV-2 传染性较强, 人群普遍易感. 野生动物宿主和患者为 SARS-CoV-2 主要传染源, 呼吸道飞沫传播和接触传播为主要传播途径. 自发现该病流行以来, 中国政府和科学界迅速明确了此次疫情病原体, 并及时向全世界公开病毒基因序列, 同时采取一系列措施控制疫情. 全球科研工作者从新型冠状病毒肺炎的病原生物学和发病机制、 流行病学、 临床特征、 诊断治疗和药物疫苗研发等各方面入手, 开展了一系列研究工作. 本文通过综述最新研究成果、 专家共识, 以及中国抗疫经验, 以期加强对该新发传染病的认识, 为防控治疗提供参考.

[1]  C. Wolf,et al.  Sequelae in Adults at 6 Months After COVID-19 Infection , 2021, JAMA network open.

[2]  D. Buonsenso,et al.  Preliminary evidence on long COVID in children , 2021, medRxiv.

[3]  Guohui Fan,et al.  RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study , 2021, The Lancet.

[4]  F. Journé,et al.  Prevalence and 6‐month recovery of olfactory dysfunction: a multicentre study of 1363 COVID‐19 patients , 2021, Journal of internal medicine.

[5]  Peter J Hellyer,et al.  Cognitive deficits in people who have recovered from COVID-19 relative to controls: An N=84,285 online study , 2020, medRxiv.

[6]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[7]  J. Cohen,et al.  Reinfection with SARS-CoV-2: Implications for Vaccines , 2020, Clinical Infectious Diseases.

[8]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[9]  J. Baeten,et al.  Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, Annals of Internal Medicine.

[10]  M. Hellwig,et al.  A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin , 2020, International Journal of Antimicrobial Agents.

[11]  C. Tebé,et al.  A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.

[12]  Amish Talwar,et al.  A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. , 2020, JAMA.

[13]  J. Ludvigsson Case report and systematic review suggest that children may experience similar long‐term effects to adults after clinical COVID‐19 , 2020, Acta paediatrica.

[14]  A.I. Eltaweel,et al.  Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic , 2020 .

[15]  E. Olsen,et al.  Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[16]  Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study , 2020, medRxiv.

[17]  David A. Drew,et al.  Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App , 2020, medRxiv.

[18]  R. Gandhi,et al.  Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2: What Goes Around May Come Back Around , 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

[19]  W. J. Boscardin,et al.  Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People , 2020, Obstetrics and gynecology.

[20]  J. Balko,et al.  Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial , 2020, medRxiv.

[21]  M. Marshall The lasting misery of coronavirus long-haulers , 2020, Nature.

[22]  C. Rhee,et al.  Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Yindalon Aphinyanaphongs,et al.  Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19 , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[24]  T. Greenhalgh,et al.  Management of post-acute covid-19 in primary care , 2020, BMJ.

[25]  Chu-Chung Huang,et al.  Cerebral Micro-Structural Changes in COVID-19 Patients – An MRI-based 3-month Follow-up Study , 2020, EClinicalMedicine.

[26]  Jay S. Steingrub,et al.  Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[27]  Manoj Sivan,et al.  Postdischarge symptoms and rehabilitation needs in survivors of COVID‐19 infection: A cross‐sectional evaluation , 2020, Journal of medical virology.

[28]  J. Dowds,et al.  Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection , 2020, medRxiv.

[29]  F. Benedetti,et al.  Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors , 2020, Brain, Behavior, and Immunity.

[30]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[31]  J. Ramos-Rincón,et al.  Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry. , 2020, Revista clinica espanola.

[32]  Yawen An,et al.  Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups , 2020, The American Journal of Geriatric Psychiatry.

[33]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[34]  Y. Tie,et al.  Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[35]  M. Heneka,et al.  Immediate and long-term consequences of COVID-19 infections for the development of neurological disease , 2020, Alzheimer's Research & Therapy.

[36]  Emily G McDonald,et al.  A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.

[37]  A. Harky,et al.  Neurological Manifestations of COVID‐19: A systematic review and current update , 2020, Acta neurologica Scandinavica.

[38]  A. Topjian,et al.  Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series , 2020, Journal of the Pediatric Infectious Diseases Society.

[39]  E. Price-Haywood,et al.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19 , 2020, The New England journal of medicine.

[40]  Zachary Schiffman,et al.  Predicting infectious SARS-CoV-2 from diagnostic samples , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Xingguang Li,et al.  Response to comments on "Cross‐species Transmission of the Newly Identified Coronavirus 2019‐nCoV” and “Codon bias analysis may be insufficient for identifying host(s) of a novel virus” , 2020 .

[42]  Kristen M J Azar,et al.  Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In California. , 2020, Health affairs.

[43]  C. Mantzoros,et al.  Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York , 2020, Metabolism.

[44]  L. Kucirka,et al.  Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure , 2020, Annals of Internal Medicine.

[45]  Angelo Mazza,et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study , 2020, The Lancet.

[46]  Hesong Zeng,et al.  Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging , 2020, JACC: Cardiovascular Imaging.

[47]  C. Gross,et al.  Racial and Ethnic Disparities in Population-Level Covid-19 Mortality , 2020, Journal of General Internal Medicine.

[48]  James M. Blum,et al.  Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 — Georgia, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[49]  H. Shan,et al.  Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase , 2020, Respiratory Research.

[50]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[51]  Hsien-Ho Lin,et al.  Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset , 2020, JAMA internal medicine.

[52]  M. Ziv,et al.  Cutaneous manifestations of COVID-19: Report of three cases and a review of literature , 2020, Journal of Dermatological Science.

[53]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[54]  Ying Yao,et al.  Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. , 2020, Journal of the American Society of Nephrology : JASN.

[55]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[56]  M. Fowkes,et al.  Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) , 2020, Journal of medical virology.

[57]  Yan-ling Ma,et al.  Antibody Detection and Dynamic Characteristics in Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Sheng Zhang,et al.  Profile of RT-PCR for SARS-CoV-2: A Preliminary Study From 56 COVID-19 Patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  Lynnette Brammer,et al.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[60]  K. Peck,et al.  Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? , 2020, International Journal of Antimicrobial Agents.

[61]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[62]  Hongliang Li,et al.  The Science Underlying COVID-19: Implications for the Cardiovascular System. , 2020, Circulation.

[63]  A. Quyyumi,et al.  Impact of Social Vulnerability on COVID-19 Incidence and Outcomes in the United States , 2020, medRxiv.

[64]  Chaochao Tan,et al.  C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early , 2020, Journal of medical virology.

[65]  Mingfang Jia,et al.  CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city , 2020, European Radiology.

[66]  Mario Plebani,et al.  Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.

[67]  Cheng Wan,et al.  Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China , 2020, Kidney International.

[68]  Y. Yazdanpanah,et al.  Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients , 2020, Emerging infectious diseases.

[69]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[70]  T. Kurita,et al.  A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs , 2020, Infectious diseases.

[71]  P. Thuluvath,et al.  Gastrointestinal and Liver Manifestations of COVID-19 , 2020, Journal of Clinical and Experimental Hepatology.

[72]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[73]  Mohammad Madjid,et al.  Potential Effects of Coronaviruses on the Cardiovascular System: A Review. , 2020, JAMA cardiology.

[74]  Jia-Fu Jiang,et al.  Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins , 2020, Nature.

[75]  Qi Jin,et al.  Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  S. Inui,et al.  Chest CT Findings in Cases from the Cruise Ship Diamond Princess with Coronavirus Disease (COVID-19) , 2020, Radiology. Cardiothoracic imaging.

[77]  Lei Liu,et al.  Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China , 2020, Diabetes Care.

[78]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[79]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[80]  Hannah R. Meredith,et al.  The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.

[81]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[83]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[84]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[85]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[86]  Lingxi Jiang,et al.  Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests , 2020, International Journal of Infectious Diseases.

[87]  Lei Liu,et al.  Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 , 2020, medRxiv.

[88]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[89]  Heshui Shi,et al.  Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet Infectious Diseases.

[90]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[91]  T. Liang,et al.  [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. , 2020, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences.

[92]  Tao Zhang,et al.  Pangolin homology associated with 2019-nCoV , 2020, bioRxiv.

[93]  Linqi Zhang,et al.  Crystal structure of the 2019-nCoV spike receptor-binding domain bound with the ACE2 receptor , 2020, bioRxiv.

[94]  Min Kang,et al.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients , 2020, The New England journal of medicine.

[95]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[96]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[97]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[98]  David Cyranoski When will the coronavirus outbreak peak? , 2020 .

[99]  G. Whittaker,et al.  Structural modeling of 2019-novel coronavirus (nCoV) spike protein reveals a proteolytically-sensitive activation loop as a distinguishing feature compared to SARS-CoV and related SARS-like coronaviruses , 2020, bioRxiv.

[100]  Shibo Jiang,et al.  The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome Coronavirus , 2020, Virologica Sinica.

[101]  Hongzhu Cui,et al.  Structural genomics and interactomics of 2019 Wuhan novel coronavirus, 2019-nCoV, indicate evolutionary conserved functional regions of viral proteins , 2020, bioRxiv.

[102]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[103]  R. Wax,et al.  Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients , 2020, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[104]  Y. Tong,et al.  Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva , 2020, medRxiv.

[105]  Huji Xu,et al.  The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS , 2020, bioRxiv.

[106]  Wei Liu,et al.  Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China , 2020, medRxiv.

[107]  Guangdi Li,et al.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.

[108]  Jie Shi,et al.  2019-nCoV epidemic: address mental health care to empower society , 2020, The Lancet.

[109]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[110]  Yan Zhao,et al.  A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.

[111]  D. Musso,et al.  2019-nCoV epidemic: what about pregnancies? , 2020, The Lancet.

[112]  Federico M Giorgi,et al.  Genomic variance of the 2019‐nCoV coronavirus , 2020, Journal of medical virology.

[113]  Q. Cui,et al.  Possible Inhibitors of ACE2, the Receptor of 2019-nCoV , 2020 .

[114]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[115]  Qiang Huang,et al.  Fast assessment of human receptor-binding capability of 2019 novel coronavirus (2019-nCoV) , 2020, bioRxiv.

[116]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[117]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[118]  Christian Drosten,et al.  The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells , 2020, bioRxiv.

[119]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[120]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[121]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[122]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[123]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[124]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[125]  Yonghong Xiao,et al.  Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm , 2020, bioRxiv.

[126]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[127]  M. Koopmans,et al.  A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. , 2020, The New England journal of medicine.

[128]  Fei Deng,et al.  Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.

[129]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of Medical Virology.

[130]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of medical virology.

[131]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[132]  N. Dong,et al.  Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China , 2020, bioRxiv.

[133]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[134]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[135]  T. Duan,et al.  Single-cell RNA expression profiling of ACE2 and AXL in the human maternal–Fetal interface , 2020 .

[136]  Bo Zhong,et al.  RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak , 2020, Emerging microbes & infections.

[137]  Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic , 2020 .

[138]  Qun Li Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020 .

[139]  Leiliang Zhang,et al.  Recent Progress in Vaccine Development Against Chikungunya Virus , 2019, Front. Microbiol..

[140]  Michael Proschan,et al.  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.

[141]  Jinping Chen,et al.  Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (Manis javanica) , 2019, Viruses.

[142]  R. Baric,et al.  Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase , 2019, Antiviral Research.

[143]  William R. Buckingham,et al.  Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. , 2018, The New England journal of medicine.

[144]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[145]  Elliot J. Lefkowitz,et al.  Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV) , 2017, Nucleic Acids Res..

[146]  S. Yadav,et al.  Post-intensive care syndrome: An overview , 2017, Journal of translational internal medicine.

[147]  Z. Memish,et al.  A cohort-study of patients suspected for MERS-CoV in a referral hospital in Saudi Arabia , 2017, Journal of Infection.

[148]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[149]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[150]  Ke Zhang,et al.  A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses , 2016, Scientific Reports.

[151]  J. Whitehead,et al.  Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol , 2015, SpringerPlus.

[152]  Jincun Zhao,et al.  Passive Immunotherapy with Dromedary Immune Serum in an Experimental Animal Model for Middle East Respiratory Syndrome Coronavirus Infection , 2015, Journal of Virology.

[153]  Gary R. Whittaker,et al.  Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis , 2014, Virus Research.

[154]  Z. Memish,et al.  Respiratory Tract Samples, Viral Load, and Genome Fraction Yield in Patients With Middle East Respiratory Syndrome , 2014, The Journal of infectious diseases.

[155]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[156]  Yuna Sun,et al.  Current progress in antiviral strategies , 2014, Trends in Pharmacological Sciences.

[157]  O. Jahn,et al.  TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein , 2013, Journal of Virology.

[158]  C. Raker,et al.  Pregnancy-induced changes in immune protection of the genital tract: defining normal. , 2013, American journal of obstetrics and gynecology.

[159]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[160]  D. Corey,et al.  Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.

[161]  Mina Abbassi-Ghanavati,et al.  Pregnancy and Laboratory Studies: A Reference Table for Clinicians , 2009, Obstetrics and gynecology.

[162]  C. Li,et al.  Host Immune Responses to SARS Coronavirus in Humans , 2009, Molecular Biology of the SARS-Coronavirus.

[163]  T. Asselah,et al.  Protease and polymerase inhibitors for the treatment of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[164]  F. Stauffer,et al.  Advances in the development of inactivated virus vaccines. , 2006, Recent patents on anti-infective drug discovery.

[165]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[166]  D. Schaffer,et al.  Antiviral RNAi therapy: emerging approaches for hitting a moving target , 2005, Gene Therapy.

[167]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[168]  N. Seidah,et al.  Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.

[169]  Shibo Jiang,et al.  Vaccine design for severe acute respiratory syndrome coronavirus. , 2005, Viral immunology.

[170]  S. Plotkin,et al.  Vaccines: past, present and future , 2005, Nature Medicine.

[171]  S. Pöhlmann,et al.  Cellular entry of the SARS coronavirus , 2004, Trends in Microbiology.

[172]  M. Iturriza-Gómara,et al.  Laboratory diagnosis of SARS. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[173]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.

[174]  M. Loeb,et al.  Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. , 2004, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[175]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[176]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[177]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[178]  Takashi Taguchi,et al.  Pulmonary fibrosis: Cellular and molecular events , 2003, Pathology international.

[179]  J. Bull,et al.  Evolutionary Dynamics of Viral Attenuation , 2002, Journal of Virology.

[180]  M. Buchmeier,et al.  Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.

[181]  A. Patick,et al.  Protease Inhibitors as Antiviral Agents , 1998, Clinical Microbiology Reviews.

[182]  M. Mayo,et al.  Virus Taxonomy , 1995, Archives of Virology Supplement 10.

[183]  J. Maniloff,et al.  Virus taxonomy : eighth report of the International Committee on Taxonomy of Viruses , 2005 .